A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)

Status

Suspended

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509569-19-00

Acronym

ANT-007

Enrollment

935

Registered

2024-07-26

Start date

2022-08-10

Completion date

Unknown

Last updated

2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

venous thromboembolism (VTE)

Brief summary

Time to first event of centrally adjudicated VTE recurrence through 6 months

Interventions

DRUGAbelacimab 150 mg/ml solution for infusion

DRUGEliquis 5 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Time to first event of centrally adjudicated VTE recurrence through 6 months	—

Countries

Austria, Czechia, France, Germany, Hungary, Ireland, Italy, Latvia, Netherlands, Norway, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026